Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK and Flagship Pioneering partner to discover novel medicines and vaccines
Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ bioplatform companies
Download (PDF, 130.7KB) -
ViiV Healthcare premieres early data showing antiviral activity against integrase resistance from its investigational, third-generation integrase inhibitor
Data, along with results from a phase I study, are the first public presentation of VH4524184.
Download (PDF, 196.9KB) -
ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1
Largest head-to-head randomised clinical trial between DTG/3TC and BIC/FTC/TAF showed DTG/3TC demonstrated non-inferior efficacy
Download (PDF, 125.5KB) -
ViiV Healthcare announces positive new data for Apretude use during pregnancy at AIDS 2024
Open label extension show maternal and pregnancy outcomes with Apretude exposure were comparable to those with no cabotegravir exposure.
Download (PDF, 125.6KB) -
Blenrep (belantamab mafodotin) combinations in multiple myeloma application accepted for review by the European Medicines Agency
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials
Download (PDF, 140.9KB) -
ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024
The presentation is one of 25 abstracts evaluating the company’s portfolio of marketed HIV treatment and prevention options.
Download (PDF, 222.3KB) -
Brazil and Thailand become first malaria-endemic countries to launch new single-dose radical cure medicine to prevent the relapse of Plasmodium vivax malaria
Launch of single-dose tafenoquine, co-administered with chloroquine, is another step closer to global elimination of malaria.
Download (PDF, 162.9KB) -
GSK and CureVac to restructure collaboration into new licensing agreement
GSK acquires full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and COVID-19.
Download (PDF, 144.1KB) -
Statement: Zantac (ranitidine) litigation – Gross case
GSK has reached a confidential settlement with Martin Gross resolving the case he filed
Download (PDF, 176.0KB) -
Statement: US Centers for Disease Control and Prevention’s Advisory Committee on Immunisation Practices updates recommendations on adult RSV vaccines ahead of the next season
GSK today announced that the US CDC ACIP voted in favour of recommending the routine use of RSV vaccines in all adults aged 75 and above.
Download (PDF, 241.0KB) -
Jemperli (dostarlimab) plus chemotherapy application accepted for review by the European Medicines Agency to expand use to all patients with primary advanced or recurrent endometrial cancer
Regulatory submission supported by statistically significant and clinically meaningful progression-free and overall survival data
Download (PDF, 143.8KB) -
GSK’s Omjjara (momelotinib) approved in Japan for treatment of myelofibrosis
Omjjara approved for use in both newly diagnosed or previously treated myelofibrosis patients.
Download (PDF, 172.0KB) -
Statement: Zantac (ranitidine) litigation – Kasza case
GSK welcomes the plaintiff's voluntary dismissal of Zantac case (Kasza) in Illinois.
Download (PDF, 137.8KB) -
Statement: Zantac (ranitidine) litigation – GSK starts process for appeal of recent Delaware Daubert decision
GSK confirms that the Company has taken the first step to seek appeal of the recent Daubert ruling, made by the Delaware Superior Court.
Download (PDF, 132.5KB) -
US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes.
Download (PDF, 224.9KB) -
GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Download (PDF, 126.4KB) -
Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024.
Download (PDF, 238.3KB) -
Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement.
Download (PDF, 217.4KB) -
Statement: Zantac (ranitidine) litigation – Delaware State Court Daubert Ruling
GSK disagrees with ruling by the Delaware State Court and will immediately seek an appeal.
-
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases
Jury in Valadez case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer
